Digestive Disease Interventions 2020; 04(04): 345-350
DOI: 10.1055/s-0040-1718902
Review Article

Adoptive Cell Therapy for Gastrointestinal Cancers

Ryan J. Slovak
1  Section of Interventional Radiology, Yale School of Medicine, New Haven, Connecticut
,
1  Section of Interventional Radiology, Yale School of Medicine, New Haven, Connecticut
2  Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut
3  Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
› Author Affiliations
Funding H.S.K. is supported by the United States Department of Defense (CA160741). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

The reinfusion of autologous or allogeneic immune cells that have been educated and/or engineered ex vivo to respond to tumor-specific antigens is termed “adoptive cell therapy.” While adoptive cell therapy has made tremendous strides in the treatment of hematologic malignancies, its utilization for solid tumors has lagged somewhat behind. The purpose of this article is to concisely review the clinical research that has been done to investigate adoptive cell therapy as a treatment for gastrointestinal malignancies.



Publication History

Received: 15 July 2020

Accepted: 18 August 2020

Publication Date:
19 November 2020 (online)

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA